AX-024

AX-024 is an orally available, first-in-class inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation with an IC50 ~1 nM. AX-024 modulates cell signaling by targeting SH3 domains. AX-024 has low-acute toxicity and high potency and selectivity, and strongly inhibit the production of IL-6, TNF-α, IFN-γ, IL-10 and IL-17A.

Product Specifications

CAS Number

[1370544-73-2]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

IFNAR; Interleukin Related; TNF Receptor

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/AX-024.html

Purity

99.73

Solubility

DMSO : 35 mg/mL (ultrasonic; warming) |Ethanol : 100 mg/mL (ultrasonic)

Smiles

COC1=CC=C(OC2)C(C(C3=CC=C(F)C=C3)=C2CN4CCCC4)=C1

Molecular Formula

C21H22FNO2

Molecular Weight

339.40

Precautions

H302, H315, H319, H335

References & Citations

[1]Borroto A, et al. First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases. Sci Transl Med. 2016 Dec 21;8 (370) :370ra184.